BioSpace News Archive

Pharm Country

Amarin Announces Comprehensive Cost Reduction Plan to Address Market Dynamics in U.S. Business

Company Expects to Achieve Approximately $100 Million in Cost Savings Over the Next 12 Months* While Continuing to Invest in European Launches and Global Expansion.

June 6, 2022
·
10 min read
Drug Development

ChemoCentryx Reports Safety Results Available from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Consistent with approved antibody inhibitors of PD-L1, CCX559 demonstrates immunomodulatory activity in first cycle of treatment.

June 6, 2022
·
6 min read
Drug Development

Treosulfan Pivotal Study Results Published

Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) today announced that the American Journal of Hematology has accepted for publication the final study results and analysis of the pivotal phase 3 clinical trial of treosulfan conducted by medac, a strategic partner of Medexus.

June 6, 2022
·
10 min read
Ryvu Therapeutics to Host Key Opinion Leader Webinar on RVU120 for the Treatment of Hematological Malignancies and Solid Tumors

KOL and Management to present on Monday, June 13, 2022 , @ 2:30pm ET.

June 6, 2022
·
3 min read
Bio NC

Seqirus Completes $156 Million Expansion to Holly Springs Manufacturing Facility, Optimizing Global Manufacturing Capabilities for Seasonal and Pandemic Influenza Vaccines

Seqirus, a global leader in influenza prevention and a business of CSL Limited, announced the completion of an expansion to the company’s manufacturing facility in Holly Springs, N.C., supporting the formulation and fill-finish of its cell-based influenza vaccines in pre-filled syringes for global communities.

June 6, 2022
·
10 min read
Business

Mirum Pharmaceuticals Appoints Saira Ramasastry to Board of Directors

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the appointment of Saira Ramasastry to the Company’s board of directors and as a member of the audit committee where she will bring to bear her more than 20 years of financial leadership.

June 6, 2022
·
4 min read
Business

NLS Pharmaceutics Appoints Chad C. Hellmann as Chief Financial Officer

NLS Pharmaceutics Ltd. announces that Chad C. Hellmann has been appointed to the position of Chief Financial Officer.

June 6, 2022
·
6 min read
Genetown

Pear Therapeutics Announces New Analysis Showing Reduction in Healthcare Resource Utilization and Associated Costs in Patients Using reSET® at Six Months

Pear Therapeutics Announces New Analysis Showing Reduction in Healthcare Resource Utilization and Associated Costs in Patients Using reSET ® at Six Months.

June 6, 2022
·
7 min read
CARsgen Therapeutics Presents Updated Data for CT041 Claudin18.2 CAR T-cells in Solid Tumors at ASCO 2022

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

June 6, 2022
·
9 min read
FDA

FDA APPROVES RIABNI™ (RITUXIMAB-ARRX), A BIOSIMILAR TO RITUXAN® (RITUXIMAB), FOR ADULTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with methotrexate for adults with moderate to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.

June 6, 2022
·
31 min read